Abiopharma

Ashland reports fourth quarter fiscal 2025 results and issues outlook for full-year 2026

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Precipio Announces Q3-2025 Shareholder Update Call

Cardinal Health Board of Directors Approves Quarterly Dividend

Guardant Health Announces Proposed Public Offering of Common Stock

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

Westlake anuncia una oferta pública de adquisición en efectivo

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

iRhythm Technologies to Participate in Upcoming Investor Conferences